Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma

Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), because IGF1R signaling is downregulated by multiple AKT and mTOR feedback mechanisms. We have tested this hypothesis in multiple myeloma using the novel selective mTOR kinase inhibitorAZD8055.We evaluatedp-mTORS as the readout formTORC2/Akt activity inmultiplemyeloma cells in the context of mTOR inhibition via AZD8055 or rapamycin. We next validated AZD8055 inhibition of mTORC1 andmTORC2 functions inmultiplemyeloma cells alone or in culturewith bonemarrow stroma cells and growth factors. Unlike rapamycin, AZD8055 resulted in apoptosis of multiple myeloma cells. AZD8055 treatment, however, induced upregulation of IGF1R phosphorylation in p-Akt S–expressing multiple myeloma cell lines. Furthermore, exposure of AZD8055-treated cells to IGF1 induced p-Akt S and rescued multiple myeloma cells from apoptosis despite mTOR kinase inhibition and TORC2/Akt blockage. The addition of blocking IGF1R antibody resulted in reversing this effect and increased AZD8055-induced apoptosis. Our study suggests that combination treatment with AZD8055 and IGF1R-blocking agents is a promising strategy in multiple myeloma with potential IGF1R/Akt signaling–mediated survival. Mol Cancer Ther; 13(11); 2489–500. 2014 AACR.

[1]  N. Munshi,et al.  New Strategies in the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[2]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[3]  Charles P. Lin,et al.  Defining the role of TORC1/2 in multiple myeloma. , 2011, Blood.

[4]  S. Pirkmajer,et al.  Serum starvation: caveat emptor. , 2011, American journal of physiology. Cell physiology.

[5]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[6]  Z. Wang,et al.  AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. , 2011, Journal of biochemistry.

[7]  E. Jacinto,et al.  mTOR complex 2 signaling and functions , 2011, Cell cycle.

[8]  Liu Wei,et al.  mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets , 2011, The Journal of Nuclear Medicine.

[9]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[10]  J. Carew,et al.  Mechanisms of mTOR inhibitor resistance in cancer therapy , 2011, Targeted Oncology.

[11]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[12]  Kenneth C. Anderson,et al.  Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma , 2010, Molecular Cancer Therapeutics.

[13]  D. Fingar,et al.  mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action* , 2009, The Journal of Biological Chemistry.

[14]  F. Giles,et al.  Potential of mTOR inhibitors as therapeutic agents in hematological malignancies , 2009, Expert review of hematology.

[15]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[16]  R. Fonseca,et al.  Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Ludwig,et al.  Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis , 2006, Cancer Immunology, Immunotherapy.

[18]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[19]  Paul Richardson,et al.  Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.

[20]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[21]  S. Rudikoff,et al.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.

[22]  Y. Shima,et al.  Isolation and characterization of human multiple myeloma cell enriched populations. , 2000, Journal of immunological methods.

[23]  A. Palumbo,et al.  Multiple myeloma. , 2011, The New England journal of medicine.

[24]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.